Bionaut Lab News Today

The two main drivers driving up the value of the oncolytic virus immunotherapy market are the rising incidence of cancer and the increase in healthcare...

The two main drivers driving up the value of the oncolytic virus immunotherapy market are the rising incidence of cancer and the increase in healthcare expenditures.Wilmington, Delaware, United States, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global oncolytic virus immunotherapy market was projected to attain US$ 110.2 million in 2022. It is anticipated to garner a 21.1% CAGR from 2023 to 2031 and by 2032, the market is likely to attain US$ 572.2 million by 2031.

Learn more about Palms-based nano robot company Bionaut Labs closing a $43M Series B funding round.

LA-based startup Bionaut Labs is developing micro-sized medical robots that are guided through the body by magnets.

Facebook’s Meta fined 265 million euros, a new study finds that smartphone addiction is linked with low self esteem and other negative cognitive outcomes, and the FCC bans the sale and imports of certain Chinese technology. That’s all the tech news that’s trending right now, welcome to Hashtag Trending. It’s Tuesday November 29 and

If this were The Matrix, you wouldn't want a robot climbing into your head. Now imagine if instead of trying to suck the life out of you, they...

Learn more about Bionaut Labs and its effort to develop nano robots to deliver drugs to treat brain cancers and other diseases.

EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut™ precision medicine treatment modality, and Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical-stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today ...